Study Progress of Diffuse Large B-Cell Lymphoma in Children
YU Ya-ping(Department of Hematology,Nanjing General Hospital of Nanjing Military Command,Nanjing 210002,Jiangsu Pro-vince,China)
Diffuse large B-cell lymphoma(DLBCL) accounts for approximately 10% of non-Hodgkin lymphomas(NHL) of childhood and encompasses a heterogeneous group of clinically and biologically different subsets. According to WHO classification,DLBCL should be assigned to one of the morphological variants:entroblastic,immunoblastic,T-cell/histiocyterich(TCHR),and anaplastic or not otherwise specified.Compared with adult DLBCL studies,immunohistochemical analysis of CD10,BCL6 and MUM-1 expression demonstrated that pediatric DLBCL cases predominantly belong to the germinal-center type B cell(GCB ) subtype.The differential diagnosis of pediatric DLBCL includes Burkitt lymphoma,primary mediastinal large B-cell lymphoma,precursor-B-cell lymphoblastic lymphoma,follicular lymphoma,nodular lymphocyte predominant Hodgkin lymphoma.Preliminary data suggest differences between DLBCL in children and adults concerning cell of origin,genetic abnormalities and responsiveness to current treatments.From recent multicentre trials on pediatric B-NHL including DLBCL,event-free survival of over 90% was reported for the subgroup of patients diagnosed with DLBCL.The potential role of monoclonal anti-CD20 antibody rituximab in the treatment of children with DLBCL remains to be determined.
【CateGory Index】： R733.1